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Epidermal growth factor receptor (EGFR) and KRAS mutations in 
non-small cell lung cancer (nsclc) patients treated with gefitinib
Sohn, Hee-Jung; Kim, Sang-We; Choi, Jene; Jang, Se Jin; Lee, Dae Ho; 
Suh, Cheolwon; Lee, Jung-Shin 
Asan Medical Center, University of Ulsan College of Medicine, Seoul, 
Korea
Background: Mutations in the tyrosine kinase domain of EGFR have 
been found to be associated with sensitivity of NSCLC to geﬁtinib. We 
analyzed the status of EGFR and KRAS mutations in advanced NSCLC 
to examine their relationship with the response to geﬁtinib. 
Methods: Between December 2001 and December 2004, a total of 199 
NSCLC patients treated with geﬁtinib (250 mg/day) at our institution. 
Sixty patients were assessable for response and had parafﬁn-embedded 
tumor tissue adequate for mutational analysis. Exons 18, 19, and 21 of 
the EGFR gene and exon 2 of the KRAS gene were sequenced. The re-
sults were then correlated with clinical features and outcome, including 
tumor response and patient survival.
Results: EGFR mutations were found in 14 patients (23%). Among 
them, 11 were in three hot-spots (G719, L747-A750, and L858), and 
novel T847A and V851L were observed in three patients. Response 
rate in patients with EGFR mutation was 79% (11 of 14 patients), in 
contrast to 22% (10 of 46 patients) in patients without mutation (P < 
.001). Moreover, these 14 patients with EGFR mutation had signiﬁ-
cantly prolonged time to progression (TTP; 7.7 v 2.4 months; P = .032). 
Patients with EGFR mutation also had better overall survival (OS), 
although it did not reach statistical signiﬁcance (19.2 v 13.6 months; P 
= .25). KRAS mutations were present in 7 of 60 patients (12%) but not 
in any tumors with EGFR mutation. Interestingly, response rates were 
similar for patients with or without KRAS mutation (43% v 34%; P = 
.23). In the multivariate analysis, EGFR mutation and adenocarcinoma 
histology were factors signiﬁcantly associated with better response and 
TTP. 
Conclusions: EGFR mutation is signiﬁcantly associated with a 
response to geﬁtinib and a longer TTP in NSCLC patients. Although re-
sponse rates were not different according to the presence of the KRAS 
mutation, whether KRAS mutational status can be used to predict 
response to geﬁtinib is still not clear. 
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Disease control with a second Epidermal Growth Factor Receptor 
(EGFR) tyrosine kinase inhibitor (TKI) after failure of a first TKI 
in Asian patients with non-small cell lung cancer (NSCLC) 
Soo, Ross1 Wong, Alvin2 Lim, Siew-Woon2 Chin, Tan-Min2 Soong, 
Richie2 
1 Dept. Haematology-Oncology, National University Hospital, Singa-
pore, 2 National University Hospital, Singapore, 
Background: Asian NSCLC patients are known to have higher re-
sponse rates to the EGFR TKI geﬁtinib (G) and erlotinib (E). Anecdotal 
reports suggest some activity for a second EGFR TKI after failure of 
the ﬁrst. 
Methods: A retrospective review of the electronic pharmacy records, 
clinical and radiographic records of patients with advanced NSCLC 
at the National University Hospital who received both G and E in the 
previous 2 years was conducted. Objectives were to assess the disease 
control (response/stable disease) of the second TKI after failure of the 
ﬁrst and characterize the clinical, pathological and molecular features 
of patients beneﬁting from a 2nd TKI. 
Results: 14 patients with advanced NSCLC who received a 2nd EGFR 
TKI after progression on the 1st TKI were identiﬁed. Patient character-
istics: Chinese 12, female 10, and non-smokers 13. Histologic subtype: 
adenocarcinoma 7, bronchioloalveolar carcinoma (BAC) 3, squamous-
cell carcinoma 1, NSCLC unspeciﬁed 3. 12 patients received cytotoxic 
chemotherapy with a median of 2 lines, (range 1-5). G and E was 
used as 1st/2nd/3rd/≥4th line treatment in 8/2/2/2 and 0/4/2/8 patients 
respectively. G was used before E in 13 cases and disease control was 
seen in 8/14 (57%) patients. With a 2nd TKI after disease progression, 
disease control was seen 4/14 (28%) patients. Patient characteristics 
were: adenocarcinoma 3, BAC 1, all were never smokers and all 
received and responded to prior G. Median duration of control in these 
4 patients for G was 8 (range 7-12) months, and subsequently to E was 
2.5 (range 2-8) months. Disease control was associated with symptom-
atic improvement. 
Conclusions: This study documents disease control in 28% of Asian 
NSCLC patients treated with a second EGFR TKI after failure of a 
ﬁrst. The molecular basis for these observations is currently being 
investigated.
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Docetaxel, Gemcitabine, and Cetuximab in Untreated Advanced 
Non-Small Cell Lung Cancer
Spigel, David R.; Greco, F. Anthony; Burris, Howard A.; Yardley, 
Denise A.; Vazquez, Elizabeth R.; Hainsworth, John D. 
Sarah Cannon Research Institute, Nashville, TN, USA
Background: Targeting the epidermal growth factor receptor has 
been a novel strategy in treating non-small cell lung cancer (NSCLC). 
Preliminary studies have found cetuximab to be safe in combination 
with platinum-based regimens in NSCLC treatment, and phase III 
investigation is ongoing. This multicenter community-based phase II 
trial was designed to examine the role of cetuximab with a non-plati-
num regimen. 
Methods: The primary endpoint is to assess the objective response 
rate (ORR). Eligibility criteria included: newly diagnosed unresectable 
stage III/IV NSCLC, measurable disease, ECOG PS 0-2, and signed in-
formed consent. Treatment: gemcitabine 1000mg/m2 IV and docetaxel 
30mg/m2 IV days 1, 8, and cetuximab 400mg/m2 day 1, then 250mg/
m2 weekly. Cycles were 21 days, and patients (pts) received 4-6 cycles. 
Pts were restaged every 6 weeks. The trial employed a 2-stage design, 
with a sample size based on achieving an ORR of 25%. 
Results: 27 pts were included in this analysis (n=66 planned). Accrual 
was temporarily suspended due to a higher than anticipated rate of 
cetuximab-based hypersensitivity reactions (HSRs). Baseline charac-
teristics included: median age 68 years (range 47-81); male / female, 
73% / 27%; and ECOG PS 0 / 1 / 2, 50% / 35% / 12% (unknown 3%); 
adenocarcinoma / squamous / large cell / unspeciﬁed, 42% / 23% / 12% 
/ 23%. The ORR was 13% (95% CI 5%-32%). 9 pts (39%) had stable 
disease and 7 pts had progressive disease. 8 pts were not evaluable be-
cause of coming off study due to: comorbidity, 2 pts; treatment-related 
toxicity, 4 pts; and pt request, 2 pts. Grade (G) 3/4 non-hematologic 
toxicity occurring in >2 pts included: fatigue, infection, and hypergly-
cemia, (12% each). G3/4 hematologic toxicity included: leukopenia 
and thrombocytopenia (19% each). There were 5 G3/4 HSRs (19%), 
including a related cardiopulmonary arrest 12 hours post-HSR. 
